Tricyclic compounds and use thereof
Novel tricyclic compounds with selective S1PR1 agonistic activity address the limitations of current S1PR1 agonists, providing effective treatment for multiple sclerosis and other autoimmune diseases.
US12637448B2Active Publication Date: 2026-05-26NANCHANG HELIOEAST PHARMA +1
Patent Information
- Application Number
- US17/905534
- Authority / Receiving Office
- US · United States
- Patent Type
- Patents(United States)
- Current Assignee / Owner
- Priority Date
- 2020-05-27
- Filing Date
- 2021-03-02
- Publication Date
- 2026-05-26
- Estimated Expiration
- 2043-06-17
Smart Images
Figure US12637448-C00001 
Figure US12637448-C00002 
Figure US12637448-C00003
Abstract
Disclosed in the present invention are a series of tricyclic compounds, and particularly disclosed are a compound shown in formula (I) or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CN102724880A
Sphingosine-1-phosphate receptor modulator and application thereof
CN107857760A
(3,4-Disubstituted)propanecarboxylic Acids as s1p(edg) Receptor Agonists
JP2007515432A
S1P1 agonists containing nitrogen-containing heterocyclyl rings
JP2012530108A
S1p1 agonists comprising a bicyclic n-containing ring
US20120101083A1